According to Data Bridge Market Research new Market report, global diabetic retinopathy treatment market accounted to USD 8.00 billion in 2017 growing at a CAGR of 6.30% during the forecast period of 2018 to 2025.
Global Diabetic Retinopathy Treatment Market
Diabetic retinopathy is an eye disease related with diabetic patients and majorly witnessed among elderly people. This disease happens when the retina is damaged owing to diabetes. Without appropriate treatment, the disease can lead to cloudy vision, bleeding in the eyes and can also destroy the retina. Diabetic retinopathy is the major reason leading to the loss of vision in diabetic patients; ultimately leading to blindness.
Global diabetic retinopathy treatment market is segmented on the basis of indication, treatment type, end user and geography.
By Type (Proliferative, Non-proliferative), Treatment Type (Laser Surgeries, Vitrectomy , Intraocular Steroid Injection, Anti-Vascular Endothelial Growth Factor drug ,), Device Type (Focal Laser Treatment, Vitrectomy Devices, Scatter Laser Treatment), Drug Type (Aflibercept, Bevacizumab, Fluocinolone, Ranibizumab, Triamcinolone Acetonide Injection), End-User (Hospitals, Ophthalmic Clinics, Ambulatory Surgical Centers), Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa)
FACTORS DRIVING GROWTH IN DIABETIC RETINOPATHY TREATMENT MARKET
Rising number of diabetic patients across the world
Diabetes is a major risk factor for diabetic retinopathy, thus rise in prevalence of diabetes is estimated to lead to the growth of market. According to World Health Organization, the number of diabetes patients has increased to 422 million in 2014 from 108 million in 1980. Further, the prevalence of diabetes has increased from 4.7 percent in 1980 to 8.5 percent in 2014 among the adults above 18 years across the world. In 2016, around 1.6 million deaths were caused due to diabetes.
Few of the major competitors currently working in diabetic retinopathy treatment market are Bayer AG, IDx Technologies Inc., Novartis AG, F. Hoffmann-La Roche Ltd, Oxurion NV, Regeneron Pharmaceuticals Inc., Sirnaomics Inc., Aerpio, ALLERGAN, Sirnaomics, Inc., Ampio Pharmaceuticals Inc., Glycadia, Inc., Alimera Sciences, Kowa Company Ltd., Bausch Health, Abbott, Pfizer Inc., IRIDEX Corporation, Lumenis, Valon Lasers..
Browse Related Reports:
Global Diabetes Treatments Market, By Product (Insulin, Oral Hypoglycemic Drugs, Non-Insulin Injectable Drugs), Devices( Blood Glucose Meters and Strips, Continuous Glucose Monitors (CGMs), Flash Glucose Monitoring Device, Injection Pens, Insulin Pumps, Automated Insulin Delivery Systems), End User (Hospital, Personal Use, Clinic), Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) – Industry Trends & Forecast to 2026
Europe Diabetes Care Devices Market By Product Type, By End-User, By Distribution Channel, By Country (Germany, France, United Kingdom, Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, Rest Of Europe) – Industry Trends and Forecast to 2024
Global Diabetes Pen Market By Indication (Type I Diabetes, Type II Diabetes), By Product Type (Insulin Pens, Insulin Pen Needles), By Type (Disposable, Reusable), By Therapy (Insulin, Glucagon-Like Peptide-1, Growth Hormones), By End Users (Hospitals, Clinics, Home Care Settings), By Geography – Industry Trends and Forecast to 2024
Global Diabetic Retinopathy Treatment Market– Industry Trends and Forecast to 2025